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Purpose: The aim of this study was to examine if package inserts (PIs) supplied with prescribed 
and over-the-counter medications in Saudi Arabia contain information relevant for the safe and 
appropriate use of these medications.
Methods: Sixty PIs for prescription-only medications (n = 37) and over-the-counter medications 
(n = 23) were evaluated against a set of safety criteria compiled from the literature.
Results: Analyzed PIs were defective in many aspects. Particularly of concern were unclear 
dosage instructions, lack of measures to be taken when an administrative error was made, inap-
propriate presentation of side effects, and lack of measures to be taken if serious side effects 
occurred.
Conclusion: This study indicated that information relevant to the safe and appropriate use of 
medications was not uniformly mentioned in the PIs analyzed. To avoid medication errors due 
to deficits in the current PIs, we recommend improvement in the existing PIs based on best 
practice for information content and design.
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Introduction
Written patient drug information, such as drug labels and package inserts (PIs), is 
intended to instruct patients on how and when to use a medicine and to promote an 
understanding of the purpose, benefits and risks of the medication prescribed.1 This 
understanding is supposed to lead to successful therapy and enable safe medication 
use. Substantial regulatory efforts have been made in Europe, the USA, and Australia 
to improve written drug information.1,2
In Saudi Arabia, during the pharmaceutical registration stage, manufacturers must 
submit a summary of product characteristics (SPC) and labeling information to the 
regulatory authority. The laws mandate that medications purchased from a community 
pharmacy are dispensed in their original packages with an insert very similar to the SPC. 
The intended users of PIs are health care professionals; however, because of their visibility 
one could expect that many patients will turn to PIs to answer their medication-related 
queries. Indeed, a Saudi-based survey of over 2000 community pharmacy customers 
found that 88% of respondents claimed that they read the PIs or ask somebody to read 
it for them.3 However, of concern is that the PIs could be the main source of information 
for some patients for many reasons. First, research suggests self-medication is common 
in Saudi Arabia.4 Second, purchasing legally prescription-only medications without 
a prescription from community pharmacies is common.5 This means that the patient 
assumes the bulk of responsibility for medication safety not only for over-the-counter 
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(OTC) medications but also for medications such as antibiotics, 
nonsteroidal anti-inﬂammatories, and oral contraceptives. 
Third, even if patients visit physicians, information provided 
regarding dose and frequency, precautions, and adverse 
effects of their prescribed medications has been shown to be 
suboptimal,6 as has community pharmacists’ counselling.7 
Despite that, research on PIs in Saudi Arabia is rare. Available 
evidence indicates that inserts of Saudi-marketed drugs 
conveyed limited and incomplete information compared 
with their counterparts marketed in the USA8 and there is 
a substantial disagreement in information between the PIs 
of generic and brand products marketed in Saudi Arabia.9 
However, no study has evaluated whether the available PIs 
are comprehensible and understandable by the patient, which 
is a very important aspect of evidence-based PIs.10 A growing 
body of research indicates that patients frequently misinterpret 
prescription drug labels and PIs.11–17 Challenges in reading 
and understanding labels and PIs may represent one cause of 
the high rates of medication errors and poor adherence.11,12 
Therefore, this study aimed to assess the availability of 
key information on PIs supplied with prescribed and OTC 
medications in Saudi Arabia. It also assessed whether 
information on PIs is presented in a way that aids patient 
comprehension. In addition, characteristics of relevance to 
readability were examined.
Methods
Pi selection
A commercially available list of top-selling prescription-only and 
OTC medications in Saudi Arabia was obtained.18 From the list 
of 253 medicines, each of which had sold 100,000 units or more 
in Saudi during the year 2011, 60 medicines were selected. The 
60 medications were chosen from the top 150 sold medications 
(prescription = 37, OTC = 23). Selection was done to ensure 
the drugs covered different therapeutic indications (n = 15), 
pharmaceutical forms (tablets, capsules, syrups, suspensions, 
drops, ointments, and inhalers), from different manufacturers 
(n = 19; four Saudi, two Arabic non-Saudi, 13 international). 
The legal status of each medication was verified by status 
information available on the Saudi Food and Drug Authority 
(SFDA) website.19 If a PI was for different strengths and one 
of these strengths was an OTC, the PI was counted with the 
OTC. The PIs were collected and analyzed by the author from 
community pharmacies in May 2011.
Leaflet characteristics
Six characteristics were examined: dimensions, layout, 
type of paper, color of paper and text, transparency, use of 
headings, and use of pictograms or graphics. Dimensions 
(length and width) of each PI were measured to the nearest 
centimeter with a standard ruler. Transparency was registered 
when print from the reverse side showed through the PI.
Evaluation criteria
PI content was evaluated using criteria derived from the 
literature – specifically, the criteria used by Fuchs et al20 and 
Raynor et al.2 Fuchs et al’s criteria were built on European 
and German regulations. Many of these quality criteria 
referred to the content of the PI, such as contraindications, 
and the dosage or possible side effects. There were also some 
criteria that considered additional aspects such as general 
comprehensibility and readability as well as layout. These 
criteria had already been used to analyze German PIs11 
and were tested in the PI test study (PAINT) study,13 which 
showed that they significantly improved comprehensibility 
and usability of PIs.12 The criteria used by Raynor and 
colleagues was based on the US Keystone Criteria,2 which 
were developed through a structured process of consensus by 
a large number of stakeholders. Criteria related to readability, 
such as word count and font size, were excluded as they were 
outside the objective of this study.
Evaluations were made on a “yes” or “no” basis with 
“yes” meaning the information was provided and “no” 
meaning no such information was provided.
Data analysis and presentation
The data were extracted by the author twice at different times 
to minimize the chances of missing any information. The 
number of PIs that met the quality criteria was calculated. 
The results were expressed as absolute numbers and 
percentages. The Chi-square test was conducted to determine 
any significant differences among groups. Statistical 
significance was determined at a P value lower than 0.05. 
All statistical analysis was performed using SPSS (v 15.00; 
IBM Corporation, Armonk, NY).
Results
Leaflet characteristics
All PIs use uncoated paper, but in all PIs the paper used was 
not sufficiently thick to reduce transparency. All analyzed PIs 
used a white background with text in black (n = 51, [85%]), 
blue (n = 7, [12%]), or red (n = 2, [3%]). Arabic translation 
was available in 58 (97%). PI headings were used in all PIs. 
Twenty (33%) analyzed PIs were in landscape format. The 
mean length of the pages on which the PIs was printed was 
26.6 cm (standard deviation [SD] 14.7), while the average 
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width of pages was 20 cm (SD 10.9). Five (8%) PIs used 
images, pictograms, or other graphics. Abbreviations and 
acronyms other than “mg,” “mL,” or “kg” were used in 21 
(35%) PIs. Scientific symbols (such as “.” or “,”) were used 
in 19 (32%) PIs. The explanation for medical terminology was 
available in eight (13%) PIs. Forty-four PIs (73%) included 
information on the last version update. The date of last update 
in 26 (65%) PIs was between 2005 and 2009. The intended 
users of the leaﬂet were specified in 10% of PIs (n = 6; two for 
health care professionals, four for patients). However, the text 
targeted particular patients in another seven (11%) PIs, evident 
from the use words such as “your medication,” “inform your 
doctor,” or “if you notice any side effects.”
All the PIs included the manufacturer’s name; however, 
four PIs (7%) did not include the manufacturer’s address. 
Approximately 82% (n = 49) provided information on correct 
storage temperature.
information provided
All PIs contained information on name, active ingredi-
ents, therapeutic indications, and pharmaceutical forms. 
Thirty-two (53%) PIs were for more than one strength and/
or different pharmaceutical forms. Although all PIs pro-
vided dosage instructions, precautions and adverse effects 
information, many lacked important information (Table 1). 
The route of administration was not explicitly indicated, such 
as “oral route” or “swallow the tablet,” in 24 (40%) analyzed 
PIs (15 OTC, nine prescription). Dosage instructions were 
given as number of tablets or capsules, as volume, drops, 
or amount of the drug instead of in milligrams of active 
Table 1 Package inserts (n = 60) content evaluation criteria
Criteria OTCa Prescriptionb Total
n % n % n %
Dosage instructions
All dosage instructions are given as number of tablets or capsules, as volume,  
drops or amount of the drug instead of in milligrams of active substance
13 57 19 51 32 53
Nonquantifiable dosage instructions, such as 1–3 times, 2–4 tablets, without  
an explanation are missing*
8 35 24 65 32 53
The maximum dose is included 9 39 15 41 24 40
The maximum dose is given as number of tablets or capsules or as volume* 6 26 2 5 8 13
Hints on period of use are available (duration of use) 10 43 20 54 30 50
Hints on time of the day when the medicine should be used 4 17 12 32 16 27
information such as take the medicine before, after, or independent of a meal  
are available in case of orally taken drugsc,*
4 24 17 59 21 46
The type of solution to use is given for orally taken drugs with a solid application formc 5 29 6 21 11 18
The amount of solution to use is given by orally taken drugs with a solid application formc,* 5 29 2 7 7 15
Hints that tablets and capsules should be taken in upright position 0 0 0 0 0 0
Provides information on what to do in case of overdose of the medicine 18 78 27 73 45 75
Provides information on what the patient should do if doses are missed* 1 4 11 30 12 20
Precautions
Statement of contraindications 22 96 36 97 58 97
Statement of drug interactions 19 83 28 76 47 78
information on laboratory, food, or herbal interactions 3 13 9 25 12 20
information on capability to drive a car or operate a machine 8 35 18 49 26 43
Provides advice on when to consult a physician/pharmacist 7 30 14 38 21 35
Adverse effects
Provides qualitative statements on the frequency of side effects (rare or common) 14 61 24 65 38 63
Verbal frequency terms are explained in the form of natural frequencies  
(eg, very common “more than 1 in 10 patients”)
2 9 8 22 10 17
Describes severity of every possible adverse reaction 3 13 5 14 8 13
Setting out the side effects by frequency of occurrence, starting with the highest 2 9 15 41 17 28
Setting side effects by organ/system/class 3 13 12 32 15 25
Statement on possible influence of the medication on reaction time* 0 0 6 16 6 10
Describes suitable measures in case of adverse reactions* 2 9 14 38 16 27
Possible side effects if medication is stopped or the dose is changed without doctor’s advice 0 0 5 14 5 8
Notes: aOTC n = 23: Nonsteroidal anti-inflammatory (n = 7), anti-pyretic analgesic (n = 5), anti-histamine (n = 5), cough preparations (n = 2), anti-ulcer (n = 3), and vitamin 
supplements (n = 1); bprescription n = 37: Antibiotics (n = 9), nonsteroidal anti-inflammatory (n = 4), hormonal contraceptive (n = 3), antihypertensive (n = 4), antidiabetic 
(n = 3), corticosteroids (n = 3), neurotropic/antiepileptic (n = 2), cough preparations (n = 2), antihypercholesterolemia (n = 2), anti-emetic (n = 2), anti-ulcer (n = 1), and 
haemorrhoids (n = 1); cpercentage calculated for oral preparation only (OTC = 17, Prescription = 29). *P , 0.05.
Abbreviation: OTC, over the counter.
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Total
Provides information on geriatric use
Provides information on pediatric use
Provides information on use in nursing women
Provides information on use in pregnant women
Prescription OTC
01 02 03 0
Percentage
40 50 60 70 80 90 100
Figure 1 Package inserts (n = 60) content evaluation criteria with regard to use in pregnant, nursing, pediatric, and geriatric populations.
Abbreviation: OTC, over the counter.
substance in 32 (52%) PIs. Thirty PIs were for tablets or 
capsules and 16 PIs were for more than one pharmaceutical 
form, including tablets or capsules. The amount of solution 
to use with tablets or capsules was given in seven of the 
analyzed tablet or capsule PIs. Recommendations that tablets 
and capsules should be taken in an upright position were not 
provided in any of analyzed PIs.
Guidance on duration of use, such as “treatment should 
not be continued for more than four weeks without medical 
advice” was available in 30 (50%) PIs. Statements on possible 
inﬂuence of the medication on reaction time, such as “this 
effect may appear after 5–7 days,” were missing in 54 (90%) 
PIs. Forty-four PIs (73%) did not provide information on 
suitable measures in case of adverse reactions even general 
measures such as “contact your doctor or pharmacist.”
There was no statistically significant difference between 
OTC and prescription-only drug PIs for most of the criteria 
(Table 1).
Information on use during pregnancy and nursing was 
available in 58 (97%) and 52 (87%) analyzed PIs, respec-
tively (Figure 1). Twenty-two (38%) PIs included information 
from animal studies on the safety or potential teratogencity. 
Instructions on possible use in children and the elderly 
could only be found in 44 (73%) and 18 (30%) PIs, respec-
tively (Figure 1). Of these PIs, only 22 (50%) provided 
information on children by age and five (28%) PIs defined 
the age of the elderly.
Discussion
In this study, Saudi PIs were analyzed to assess if they 
  contained information the patient could understand and 
  follow to their best possible benefit. As Table 1 makes 
clear, PIs had many deficiencies. Particularly of concern 
was the lack of clarity in dosing instructions. Medication 
errors and adverse events in the outpatient setting have 
been linked to patients’ unintentional misuse of prescribed 
or OTC medicines due to improper understanding of PI 
instructions, particularly in patients with limited literacy 
skills and those managing multiple medication regimens.11,12 
Evidence suggests that patients are more likely to make an 
error if dosage instructions were given in milligrams of 
active substance instead of number of tablets.11–13 Patients 
are   better able to interpret more explicit instructions, 
for example, “every 12 hours,” compared with the more 
implicit “twice daily.”11,12 Also, their ability to determine the 
correct dose is reduced if presented with instructions such 
as “take 2–4 tablets.”13 Yet, approximately half of analyzed 
PIs presented dosage instructions this way. Evidence also 
suggests that when taking orally administered tablets, people 
should drink a minimum of 60 mL of liquid and position 
the upper body at a minimum angle of 45° to achieve a high 
passage rate of tablets or capsules.21 Such instructions were 
missing in many of the analyzed PIs.
Of concern also is reporting of side effects. Very few 
PIs presented the likelihood of adverse effects using the 
recommended approach of verbal descriptions alongside 
natural frequencies, for example, “very common (more than 
1 in 10 patients).” The use of verbal expressions alone or 
percentages are misunderstood and can lead to overestimation 
of the risk by the user,14,15 which may deter patients from tak-
ing their medication.22 Only 28% of analyzed PIs presented 
side effects grouped in terms of frequency and severity, which 
is more comprehensible for patients than organ systems.16
Patients are entitled to better information with their 
medication to enable them to make informed decisions as to 
whether to take the drug and to prepare them for what they 
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might experience in response to a drug.1 However, analyzed 
PIs were often unclear about patient actions, such as what 
they should do if they miss a dose, what measures should 
be taken if serious side effects occur, and when to consult 
a doctor.
The problems identified in this study largely conform 
to those noted by others who examined patient information 
leaﬂets.2,15,20,23–27 An international research group compared 
five patient information leaﬂets from the UK with five from 
Australia and four from the USA.2 Leaﬂets from Australia 
showed the best quality, closely followed by those of the UK. 
The US leaﬂets were not only found lacking in provision of 
information about contraindications, precautions, and drug 
interactions, but also in readability and comprehensibility.2 
An investigation of 68 German PIs from frequently used 
medicines20 found that many inserts lacked key safety 
information, including information on daily maximum 
dose and adverse effects, and were difficult to comprehend. 
Carrigan et al15 assessed the leaflets supplied with the 
50 most frequently prescribed drugs in England and found 
that 20 (40%) of the 50 leaﬂets gave no indication of the 
likelihood of adverse effects occurring and only four leaﬂets 
(8%) provided any form of numerical indication of risk. 
Analysis of PIs accompanying marketed drug products in 
India (n = 80) found only five of the inserts had information 
on the most frequent adverse drug reactions associated with 
the drug.24 Also, information with regard to pediatric and 
geriatric use was present in only 44% and 13% of the PIs, 
respectively. Other studies on PIs for topical medications 
(n = 15),25 geriatric medications (n = 50),26 and antidepressants 
(n = 42),27 similarly found PIs lacking in adequate information 
about contraindications, precautions and drug interactions.
This study has three main limitations that should be 
considered when interpreting the results. First, a small 
number of PIs were analyzed. Second, PI samples were not 
collected randomly, which raises the possibility of selection 
bias. As a result, it may be possible that randomly choosing 
the PIs and increasing the sample size could lead to differ-
ences in the results found. However, considering the diversity 
of PIs examined with regards to indications, legal status, and 
manufacturers, other important findings are quite unlikely. 
Moreover, the number of PIs examined is in the range of 
sample size of previous similar research. Third, there are 
no gold standard criteria for evaluating written patient drug 
information28 and criteria used in this study, although used in 
previous research, have advantages and disadvantages.
Despite these limitations, this study represents the first 
attempt to evaluate PI adequacy as sources of information 
for patients in Saudi Arabia. The results presented here 
demonstrate the necessity and possibilities to improve PIs. 
Fortunately, from August 2011, a patient information leaﬂet 
(PIL) is now required to be submitted during the drug 
registration process.29 This does not mean, however, that the 
issues highlighted by this research will be fully resolved. 
It is not clear if or when PILs will replace the current PIs. 
Until the newly implemented PILs are widely available, most 
Saudi patients will receive no written information other than 
the PIs analyzed in this study. Furthermore, legislation and 
guidelines in other countries have not guaranteed that PIs 
are clear and easy to use. The SFDA guidelines state that PILs 
should be written “using patient understandable language,” 
but provide no directions on what constitutes patient 
understandable language. Evidence suggests that specific 
content and format of prescription drug labels facilitate 
communication with and comprehension by patients.17,30 We 
recommend, therefore, that the SFDA guideline demands 
the use of evidence-based best practices regarding how 
medication information should be written, designed, and 
delivered. Patient characteristics such as education and 
age have an effect on their understanding and usability of 
PIs.11,12,16,31 Thus, the SFDA should also require that PILs 
reﬂect the results of consultations with target patient groups, 
to understand fully the diverse needs of our patients. The 
mode of PI delivery, whether it is computer generated as in 
the USA, a PI as in Europe, or online via the SFDA website, 
also requires careful consideration.
The findings of this study should stimulate further 
research into the effects of content and format of PIs 
on readability, understanding, and medication use. The 
current study did not assess actual patient understanding 
of medication instructions; rather, it used criteria to 
measure comprehensibility and understandability. Research 
measuring actual patients’ abilities to understand and act 
upon instructions provided in PIs is required. This paper 
has focused on the availability of key information and its 
comprehensibility, with less emphasis on the readability of 
PIs. Further research in this area is needed. The effect of 
alternative PI design and layout on comprehension among 
patients across all age groups and literacy levels also needs 
to be investigated. As the nature of the relationship between 
deficits in PIs and poor medication-taking behavior (ie, 
adherence) or unsafe use of medications has not been well 
tested,17 more studies evaluating the effects of PI content 
and format on adherence, medication error rates and health 
outcomes are needed. The design of these studies needs to 
capture the true complexity of medication-taking behavior, 
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where patients may be taking multiple medications and have 
numerous competing demands.
Conclusion
This study indicates that information relevant to the safe and 
appropriate use of medications was not uniformly   provided in 
the PIs analyzed. To avoid medication errors due to   deficits in 
the current PIs, we recommend improvement in the existing PIs 
based on best practice for information content and design.
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